论文部分内容阅读
目的:观察冠脉内支架置入术后低分子肝素和普通肝素的临床疗效。方法:将研究对象49例分为普通肝素组22例及低分子肝素组27例。观察两组急性、亚急性支架内血栓形成发生例数及术后半个月内严重心脏事件的发生情况。统计两组出血副作用的发生例数。结果:低分子肝素组发生急性、亚急性支架内血栓形成及术后半个月内心脏严重事件的发生例数均低于普通肝素组,但无统计学差异(P>0．05)。低分子肝素组出血发生率明显低于普通肝素组(P<0．05)。结论:低分子肝素抗凝疗效与普通肝素相似,而出血事件明显少于普通肝素,且无需监测,值得推广应用。
Objective: To observe the clinical effect of low molecular weight heparin and unfractionated heparin after coronary stenting. Methods: 49 subjects were divided into 22 cases of unfractionated heparin group and 27 cases of low molecular weight heparin group. The number of acute and subacute stent thrombosis and the occurrence of severe cardiac events within two months after operation were observed. Statistics two cases of bleeding occurred side effects of the number of cases. Results: Acute and subacute stent thrombosis occurred in low molecular weight heparin group and the number of serious cardiac events within half a month after operation were lower than those in unfractionated heparin group (P> 0.05). The incidence of hemorrhage in low molecular weight heparin group was significantly lower than that in unfractionated heparin group (P <0.05). Conclusion: The anticoagulant effect of low molecular weight heparin is similar to that of unfractionated heparin, and the bleeding events are obviously less than that of unfractionated heparin, and it is worth noting that it is worthy of popularization and application.